Abbott MO5-730
A phase 3, randomized, open-label, study of Lopinavir/ritonavir tablets versus soft gel capsules and once daily versus twice daily adminstration, when co-administered wtih NRTI's in antiretroviral...
Tibotec TMC114-C226
Early access of TMC114 in combination with low dose RTV and other ARV's in highly treatment experienced HIV-1 infected subjects with limited to no treatment options.
Inclusion criteria -- Male...
Schering-Plough PO4100
Vicriviroc (Sch417690) Treatment Protocol in HIV infected subjects; a rollover study for ACTG protocol A5211.
Inclusion criteria -- completion of week 48 A5211 on an RTV containing ARV...
Tibotec TMC125-C216
A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC 125 as part of an ART including TMC114/RTV and an investigator-selected...
Merck 019-00 BENCHMRK
A multi-center, double-blind, randomized, placebo-controlled study to evaluate the safety and antiretroviral activity of MK-0518 in combination with an optimized baackground therapy, versus optimized...
GlaxoSmithKline EPZ 104057 HEAT
A 96-week, Phase IV, randomized, double-blind, multi-center study of the safety and efficacy of Epzicom versus Truvada administered in combination with Kaletra in antiretroviral naive HIV-1 infected...
GlaxoSmithKline 100290
ELECT - A Phase IIIB/IV, Open-Label, Multi-Center Trial to Evaluate the Safety, Tolerability, and Efficacy of HIV-1 Infected Subjects Switching Their Current Protease Inhibitor Therapies for a...
Pfizer A400 1027
CCR5 inhibitor for HIV-1 experienced patients.
Inclusion criteria - VL >5000, ARV’s at least 4 wks, documented resistance, CCR5 tropism.
Exclusion criteria - Untreated OI, AST/ALT > 5x ULN,...
Bristol Myers Squibb IMPACT
IMPACT – A phase IV, multi-center, cross-sectional study to evaluate the 150L substitution among subjects experiencing Virologic failure on a HAART regimen containing Atazanavir. LABS ONLY – one...
Hoffman-LaRoche NV 17751
T-20 - Prospective observational cohort study of pneumonia in Fuzeon-exposed and non-exposed patients. Chart review only.
Inclusion criteria - Treatment experienced, CD4 < and/or = 400, Fuzeon...
Boehringer Ingelheim 1182.12
RESIST - Randomized, open-label comparative study of Tipranavir boosted with low dose Ritonavir versus genotypically-defined protease inhibitor in experienced patients.
Inclusion Criteria - Closed...
|
